![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-300x278.jpg)
![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-e1650536525880.jpg)
news
Samsung Bioepis fully acquired by Samsung Biologics
After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.
List view / Grid view
Samsung Bioepis
article
Biosimilar uptake: a clinician’s perspective
To ensure that clinicians buy into biosimilars, it is important that they understand how products are analysed and compared to the originator molecules. Dr Fraser Cummings and Jonathan Sweeting discussed this issue at a recent virtual roundtable event, where they highlighted the complexities of biosimilar development pathways and approval processes. Here, Nikki Withers shares the…
article
The rise of biosimilars – navigating regulatory complexity in Europe
Gabriela Marton sets out some of the EU-associated regulatory challenges life sciences companies will need to navigate if they want to take advantage of the rise of biosimilars.
news
Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
news
Infliximab biosimilar Flixabi approved in the EU
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
news
EC approves Benepali – the first biosimilar of Enbrel
18 January 2016 | By Victoria White
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there...
news
Benepali receives positive opinion from CHMP
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
news
Merck and Samsung Bioepis enter collaboration agreement to develop and commercialize insulin glargine candidate for diabetes
10 February 2014 | By Merck
Merck and Samsung Bioepis Co., Ltd., announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293...
news
Biogen Idec and Samsung Bioepis announce agreement to market anti-TNF biosimilar product candidates in Europe
17 December 2013 | By Biogen Idec
Biogen Idec opts-in to commercialization opportunity with joint venture partner...
news
Samsung Biologics and Biogen Idec announce formation of biosimilars joint venture Samsung Bioepis
27 February 2012 | By Biogen Idec
Samsung Biologics & Biogen Idec have established their joint venture...
